{
    "clinical_study": {
        "@rank": "119338", 
        "arm_group": [
            {
                "arm_group_label": "Linagliptin in TD2 subjects", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin in TD2 subjects with normal renal function"
            }, 
            {
                "arm_group_label": "Linagliptin in TD2 subjects with impaired renal function", 
                "arm_group_type": "Experimental", 
                "description": "Linagliptin in TD2 subjects with impaired renal function"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a bi-centric, prospective, open study comparing the effects of linagliptin on active\n      GLP-1 concentrations in subjects with renal impairment compared to subjects with normal\n      renal function."
        }, 
        "brief_title": "Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have Type 2 diabetes mellitus based on the disease diagnostic criteria (WHO)\n             classification\n\n        Exclusion Criteria:\n\n          -  Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or\n             secondary forms of diabetes such as due to pancreatitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903070", 
            "org_study_id": "00/0594-LINARI"
        }, 
        "intervention": {
            "arm_group_label": [
                "Linagliptin in TD2 subjects", 
                "Linagliptin in TD2 subjects with impaired renal function"
            ], 
            "intervention_name": "Linagliptin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "BI 1356"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "email": "regulatory@profil.com", 
                "last_name": "Judith Beer", 
                "phone": "+4921314018", 
                "phone_ext": "145"
            }, 
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "41460"
                }, 
                "name": "Profil Institut f\u00fcr Stoffwechselforschung GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "EFFECTS OF LINAGLIPTIN ON ACTIVE GLP-1 CONCENTRATIONS IN SUBJECTS WITH RENAL IMPAIRMENT", 
        "overall_contact": {
            "email": "christoph.kapitza@profil.com", 
            "last_name": "Christoph Kapitza, MD", 
            "phone": "+4921314018", 
            "phone_ext": "157"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u0394AUCGLP-1-OGTT(0-240) Change in active GLP-1 concentrations after oral glucose ingestion after linagliptin Treatment compared between Groups.", 
            "measure": "\u0394AUCGLP-1-OGTT(0-240)", 
            "safety_issue": "No", 
            "time_frame": "Glucose tolerance test following 7 days of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Profil Institut f\u00fcr Stoffwechselforschung GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Profil Institut f\u00fcr Stoffwechselforschung GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}